{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:44:20Z","timestamp":1792899860115,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T00:00:00Z","timestamp":1616544000000},"content-version":"vor","delay-in-days":388,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jacc.2019.12.069","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T16:16:17Z","timestamp":1584375377000},"page":"1281-1295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":208,"title":["Multiple Plasma Biomarkers for Risk\u00a0Stratification in Patients With Heart\u00a0Failure\u00a0and Preserved Ejection Fraction"],"prefix":"10.1016","volume":"75","author":[{"given":"Julio A.","family":"Chirinos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Orlenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ellen","family":"Cvijic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuyin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Spires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Yarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar A.","family":"Seiffert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Prenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Payman","family":"Zamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupam","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Margulies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Car","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason H.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Cappola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2019.12.069_bib1","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ahj.2011.09.007","article-title":"Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction","volume":"162","author":"Desai","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2019.12.069_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in\u00a0the Treatment of Preserved Cardiac Function Heart\u00a0Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.12.069_bib3","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.12.069_bib4","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1093\/eurheartj\/ehy005","article-title":"Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study","volume":"39","author":"Lam","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.12.069_bib5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jacc.2011.03.032","article-title":"The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure","volume":"58","author":"Ky","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.12.069_bib6","article-title":"Thyroid dysfunction in heart failure and cardiovascular outcomes","volume":"11","author":"Lakshmi","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2019.12.069_bib7","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jacc.2019.01.020","article-title":"Soluble FMS-like tyrosine kinase-1 is a circulating biomarker associated with calcific aortic stenosis","volume":"73","author":"Small","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.12.069_bib8","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1126\/science.1144581","article-title":"The product space conditions the development of nations","volume":"317","author":"Hidalgo","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.jacc.2019.12.069_bib9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-3-319-31204-0_9","article-title":"Automating biomedical data science through tree-based pipeline optimization","author":"Olson","year":"2016","journal-title":"Applications of Evolutionary Computation"},{"key":"10.1016\/j.jacc.2019.12.069_bib10","first-page":"460","article-title":"Considerations for automated machine learning in clinical metabolic profiling: Altered homocysteine plasma concentration associated with metformin exposure","volume":"23","author":"Orlenko","year":"2018","journal-title":"Pac Symp Biocomput"},{"key":"10.1016\/j.jacc.2019.12.069_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12065-015-0128-8","article-title":"ExSTraCS 2.0: Description and evaluation of a scalable learning classifier system","volume":"8","author":"Urbanowicz","year":"2015","journal-title":"Evol Intell"},{"key":"10.1016\/j.jacc.2019.12.069_bib12","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/eurheartj\/ehs337","article-title":"Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies","volume":"34","author":"Pocock","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.12.069_bib13","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A\u00a0novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.12.069_bib14","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/ejhf.414","article-title":"Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction","volume":"17","author":"Sanders-van Wijk","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2019.12.069_bib15","first-page":"338","article-title":"Growth differentiation factor-15 is a useful prognostic marker in patients with heart failure with preserved ejection fraction","volume":"30","author":"Izumiya","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2019.12.069_bib16","article-title":"Fibroblast growth factor-23 and heart failure with reduced versus preserved ejection fraction: MESA","volume":"7","author":"Almahmoud","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2019.12.069_bib17","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1161\/CIRCHEARTFAILURE.115.002341","article-title":"Fibroblast growth factor 23 is an independent and specific predictor of mortality in patients with heart failure and reduced ejection fraction","volume":"8","author":"Koller","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2019.12.069_bib18","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2019.12.069_bib19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1161\/CIRCHEARTFAILURE.113.000952","article-title":"Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis","volume":"7","author":"Kestenbaum","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2019.12.069_bib20","first-page":"23","article-title":"Fatty acid-binding protein 4 (FABP4): pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases","volume":"8","author":"Furuhashi","year":"2014","journal-title":"Clin Med Insights Cardiol"},{"key":"10.1016\/j.jacc.2019.12.069_bib21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12933-014-0126-7","article-title":"Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population","volume":"13","author":"Fuseya","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2019.12.069_bib22","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/heartjnl-2013-303735","article-title":"Fatty acid binding protein 4 predicts left ventricular mass and longitudinal function in overweight and obese women","volume":"99","author":"Engeli","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2019.12.069_bib23","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1161\/ATVBAHA.107.146274","article-title":"Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis","volume":"27","author":"Yeung","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2019.12.069_bib24","doi-asserted-by":"crossref","first-page":"35282","DOI":"10.1038\/srep35282","article-title":"Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"6","author":"Kumagai","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2019.12.069_bib25","first-page":"507","article-title":"Biomarker profiles of acute heart failure patients with a mid-range ejection fraction","volume":"5","author":"Tromp","year":"2017","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2019.12.069_bib26","article-title":"Biomarker profiles in heart failure patients with preserved and reduced ejection fraction","volume":"6","author":"Tromp","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2019.12.069_bib27","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2459\/JCM.0000000000000229","article-title":"Relationship between osteoprotegerin and mortality in decompensated heart failure with preserved ejection fraction","volume":"16","author":"Aramburu-Bodas","year":"2015","journal-title":"J\u00a0Cardiovasc Med (Hagerstown)"},{"key":"10.1016\/j.jacc.2019.12.069_bib28","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1161\/CIRCHEARTFAILURE.110.960716","article-title":"Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy","volume":"4","author":"Krum","year":"2011","journal-title":"Circ Heart Fail"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109720302631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109720302631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:31:50Z","timestamp":1760016710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109720302631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0735109720302631"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2019.12.069","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple Plasma Biomarkers for Risk\u00a0Stratification in Patients With Heart\u00a0Failure\u00a0and Preserved Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2019.12.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}